当前位置：
X-MOL 学术
›
Stem Cell Res. Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Pimecrolimus interferes the therapeutic efficacy of human mesenchymal stem cells in atopic dermatitis by regulating NFAT-COX2 signaling
Stem Cell Research & Therapy ( IF 7.5 ) Pub Date : 2021-08-28 , DOI: 10.1186/s13287-021-02547-8 Nari Shin 1 , Namhee Jung 2 , Seung-Eun Lee 1 , Dasom Kong 1 , Nam Gyo Kim 1 , Myung Geun Kook 1 , Hwanhee Park 2 , Soon Won Choi 1 , Seunghee Lee 2 , Kyung-Sun Kang 1
Stem Cell Research & Therapy ( IF 7.5 ) Pub Date : 2021-08-28 , DOI: 10.1186/s13287-021-02547-8 Nari Shin 1 , Namhee Jung 2 , Seung-Eun Lee 1 , Dasom Kong 1 , Nam Gyo Kim 1 , Myung Geun Kook 1 , Hwanhee Park 2 , Soon Won Choi 1 , Seunghee Lee 2 , Kyung-Sun Kang 1
Affiliation
Human mesenchymal stem cells (hMSCs) therapy has recently been considered a promising treatment for atopic dermatitis (AD) due to their immunomodulation and tissue regeneration ability. In our previous studies, we demonstrated that hMSCs alleviate allergic inflammation in murine AD model by inhibiting the activation of mast cells and B cells. Also our phase I/IIa clinical trial showed clinical efficacy and safety of hMSCs in moderate-to-severe adult AD patients. However, hMSCs therapy against atopic dermatitis have had poor results in clinical field. Therefore, we investigated the reason behind this result. We hypothesized that drug–cell interaction could interfere with the therapeutic efficacy of stem cells, and investigated whether coadministration with pimecrolimus, one of the topical calcineurin inhibitors, could influence the therapeutic potential of human umbilical cord blood mesenchymal stem cells (hUCB-MSCs) in AD. hUCB-MSCs were subcutaneously injected to AD-induced mice with or without pimecrolimus topical application. To examine whether pimecrolimus influenced the immunomodulatory activity of hUCB-MSCs, hUCB-MSCs were treated with pimecrolimus. Pimecrolimus disturbed the therapeutic effect of hUCB-MSCs when they were co-administered in murine AD model. Moreover, the inhibitory functions of hUCB-MSCs against type 2 helper T (Th2) cell differentiation and mast cell activation were also deteriorated by pimecrolimus treatment. Interestingly, we found that pimecrolimus decreased the production of PGE2, one of the most critical immunomodulatory factors in hUCB-MSCs. And we demonstrated that pimecrolimus downregulated COX2-PGE2 axis by inhibiting nuclear translocation of NFAT3. Coadministration of pimecrolimus with hMSCs could interfere with the therapeutic efficacy of hMSCs in atopic dermatitis, and this is the first study that figured out the interaction of hMSCs with other drugs in cell therapy of atopic dermatitis. Therefore, this study might give rise to improvement of the clinical application of hMSCs therapy and facilitate the widespread application of hMSCs in clinical field.
更新日期：2021-08-29
京公网安备 11010802027423号